ASX Announcements
Notification of cessation of securities - MYX
Appendix 3H (Notification of cessation of securities)
- Jan 15, 2025
- 4 pages
Notification of cessation of securities - MYX
Appendix 3H (Notification of cessation of securities)
- Jan 7, 2025
- 4 pages
Notification regarding unquoted securities - MYX
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities)
- Dec 6, 2024
- 6 pages
November 2024
Jefferies Australia fields bidder interest for Mayne Pharma Group
Almost 90 per cent of Mayne’s revenue comes from ex-Australia customers suggesting it may be difficult to prosecute a strong argument for keeping it wedded to ASX.
- Sarah Thompson, Kanika Sood and Emma Rapaport
May 2023
Infomedia wrangler Viburnum butts heads with Mayne Pharma’s board
The listed drugmaker is in the firing line of the activist investor, which is taking the board to task for paring back a $113 million capital raising.
- Sarah Thompson, Kanika Sood and Emma Rapaport
August 2021
Mayne Pharma’s net losses more than double
A weaker US dollar, COVID-19 and a tough US generics market has hurt the company, with sales and earnings down double digits in fiscal 2021.
- Carrie LaFrenz
Mayne Pharma hit with investor class action
Mayne was targeted in investigations by the US Department of Justice and the Office of the Attorney General in Connecticut.
- Carrie LaFrenz
April 2021
Mayne wins FDA approval for oral contraceptive
Ten million American women take combined hormonal contraceptives, presenting a major market opportunity for Mayne Pharma, whose stock jumped over 15 per cent to 53¢ on the news.
- Carrie LaFrenz
February 2021
Mayne Pharma hopes for FDA nod after half-year loss widens to $182m
The company’s results were hit by the weakening US dollar, challenging trading conditions from COVID-19 and softer earnings on generics.
- Carrie LaFrenz
August 2020
ASX down 0.2pc for week; Westpac says $A to hit US80¢
The Australian sharemarket fell 0.1 per cent on Friday as CSL, BHP and Commonwealth bank weighed on the index. Suncorp rallied 11 per cent. Westpac's Bill Evans lifts 2020 and 2021 Australian dollar forecasts.
- Robert Guy, Vesna Poljak, Sarah Turner, William McInnes, Luke Housego and Tom Richardson
June 2020
The stocks to watch in the COVID-19 era
Can the stocks that have risen the fastest after the start of COVID-19 maintain the momentum? Stewart Oldfield outlines what to keep an eye on, especially during the upcoming reporting season.
- Stewart Oldfield
February 2020
Generics take big bite from Mayne Pharma
The specialty pharmaceutical company swings into the red as sales tumble 17 per cent.
- Carrie LaFrenz
May 2019
Mayne Pharma plunges 15pc as generic business drags
Shares of Mayne Pharma Group fell as much as 15.8 per cent, touching a four-year low.
February 2019
Mayne Pharma ready for US healthcare reform
The chief of pharmaceutical manufacturer Mayne Pharma is expecting "significant legislative change" to US drug prices.
- Updated
- Liz Main
December 2018
Buy, hold, sell: Service Stream, Mayne Pharma, G8 Education, Arena REIT
Centennial Funds' Matthew Kidman talks with Tobias Yao from Wilson Asset and Arden Jennings from Ausbil about stormy markets.
- Updated
November 2018
Are currencies signalling time to realign portfolios for a weaker US dollar?
A sea change may be happening in the currency markets, putting at risk the outsized returns that Australian investors have enjoyed this year and paving the way for portfolio rotation.
- Updated
- Sarah Turner
October 2018
Wilson Asset Management's new partnership rises from Slater & Gordon debacle
One was in his fund's dealing room when the Slater & Gordon debacle unfolded, the other was a lone critical voice on the sell-side. Now they're together and have the keys to invest about $1.9 billion. And it sounds like lessons from the past are fresh in their memories.
- Updated
- Anthony Macdonald
August 2018
Mayne Pharma swings to $134m full-year loss, paints better outlook
Mayne Pharma Group boss Scott Richards says the outlook is positive across the specialty pharmaceutical group with a more stabilised US retail generic pricing environment which dented sales and profitability in the 2018 financial year.
- Updated
- Carrie LaFrenz
May 2018
How the Rich Invest: Alan Wilson
The wealth of billionaire Alan Wilson and his family been surging on the rising price of shares in Reece group. But that's not all.
- Updated
- John Stensholt
November 2017
Mayne Pharma's Scott Richards loses 7.3m shares in Credit Suisse margin call
Zurich just backed up the truck and turned up the radio! Margin loans so often end this way.
- Updated
- Joe Aston
Mayne Pharma hit by falling generic drug prices
Drugs manufacturer Mayne Pharma is still feeling the impact of tough competition and lower prices in the generic drugs market in the US.
- Updated
- Trevor Chappell
How the Rich Invest: Bruce Mathieson helps Woolworths cash in on pubs, pokies
Rich Lister Bruce Mathieson and his pubs and pokies partner Woolworths have enjoyed a big year for their joint venture ALH.
- Updated
- John Stensholt
September 2017
Being informed beats being early says Greencape's Matt Ryland
Greencape Capital's Matt Ryland says their edge comes from limiting their fund size and not limiting their travel budget.
- Updated
- Jonathan Shapiro